


PHARMACEUTICAL 2022

Aptevo Therapeutics Inc. Rank 386 of 466







PHARMACEUTICAL 2022



Aptevo Therapeutics Inc. Rank 386 of 466

The relative strengths and weaknesses of Aptevo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptevo Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Aptevo Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -47%, being 125% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	52,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,757
Liabilities, Non-Current	1,341
Other Assets	1,652
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	19,287
Other Net Income	-7,057
Other Revenues	12,292
Property and Equipment	2,379
Research and Development	18,994
Selling, General and Administrative Expense	14,698

Output Variable	Value in 1000 USD
Assets	56,601
Liabilities	55,385
Expenses	33,692
Revenues	12,292
Stockholders Equity	1,216
Net Income	-28,457
Comprehensive Net Income	-28,457
Economic Capital Ratio	-47%

